In a new study, NCI-led researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a type of immunotherapy.

NCI’s Steven A. Rosenberg, M.D., Ph.D., and two NCI-supported researchers have been named recipients of the 2018 Albany Medical Center Prize in Medicine and Biomedical Research for their pioneering immunotherapy research.

Results from a randomized clinical trial show patients with HPV-positive oropharyngeal cancer treated with radiation and cetuximab had inferior survival compared to the current standard treatment with radiation and cisplatin. The trial’s goal was to find a less toxic treatment approach without compromising survival.

A fact sheet about human papillomavirus (HPV) vaccines for the prevention of infection with certain types of HPV, which is the major cause of cervical cancer.

A fact sheet that provides an overview of how the immune system functions and describes the actions of biological therapies, such as monoclonal antibodies, cytokines, therapeutic vaccines, the bacterium bacillus Calmet-Guérin, cancer-killing viruses, gene therapy, and adoptive T-cell transfer.

A fact sheet that describes targeted cancer therapies, which are drugs that interfere with specific molecules involved in cancer cell growth and survival.